325
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Efficacy of low-dose vaginal 17β-estradiol versus vaginal promestriene for vulvovaginal atrophy

, &
Pages 383-387 | Received 04 Aug 2021, Accepted 14 Oct 2021, Published online: 23 Nov 2021

References

  • Mili N, Paschou S, Armeni A, et al. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. Menopause. 2021;28(6):706–716.
  • Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167–173.
  • Palma F, Xholli A, Cagnacci A. The most bothersome symptom of vaginal atrophy: evidence from the observational AGATA study. Maturitas. 2018;108:18–23.
  • Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508–516.
  • Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020;27:976–992.
  • Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068.
  • DiBonaventura M, Luo X, Moffatt M, et al. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. J Women’s Health. 2015;24(9):713–722.
  • Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–291.
  • Nappi R, Martini E, Cucinella L, et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for healthy aging in women. Front Endocrinol (Lausanne). 2019;10:561.
  • Cotreau M, Chennathukuzhi V, Harris H, et al. A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas. 2007;58(4):366–376.
  • Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321–1330.
  • Lindén Hirschberg A, Bitzer J, Cano A, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. Maturitas. 2021;148:55–61.
  • Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: Implications for clinical practice. J Women's Health. 2008;17:569–578.
  • Minkin M, Maamari R, Reiter S. Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Women’s Health. 2013;5:133–139.
  • Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010;13:219–227.
  • Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study. Maturitas. 2012;72:93–94.
  • Dugal R, Hesla K, Sørdal T, et al. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand. 2000;79(4):293–297.
  • Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995;22:S1–S5.
  • Meisels A. The maturation value. Acta Cytol. 1967;11(4):249.
  • Rioux J, Devlin C, Gelfand M, et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000;7:156–161.
  • Hosseinzadeh P, Ghahiri A, Daneshmand F, et al. A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010–2012. J Res Med Sci. 2015;20(12):1160–1165.
  • Mattsson LÅ, Ericsson Å, Bøgelund M, et al. Women’s preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy. Maturitas. 2013;74(3):259–263.
  • Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms. JAMA Intern Med. 2018;178:681–690.
  • Lukas VA, Simon JA. MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence. Menopause. 2020;27(6):722–725.
  • Ilhan G, Aslan MM, Cevrioglu AS, et al. Clinical efficacy of hormonal and nonhormonal agents in the treatment of vulvovaginal atrophy. J Menopausal Med. 2021;27:15.
  • Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause–cytology, histology and pH as methods of assessment. Maturitas. 1995;21(1):51–56.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.